ArticleBioengineered2022

Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias.

Sisi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.